VVM
Versant Venture Management Portfolio holdings
AUM
$82.1M
This Quarter Return
-16.92%
1 Year Return
-26.22%
3 Year Return
+73.87%
5 Year Return
-1.11%
10 Year Return
+1,578.11%
AUM
$65.2M
AUM Growth
+$65.2M
(-35%)
Cap. Flow
-$17.8M
Cap. Flow
% of AUM
-27.25%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
–
Reduced
–
Closed
2
Top Buys
No buys this quarter
Top Sells
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$9.01M |
| 2 |
Akero Therapeutics
AKRO
|
$8.77M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CRISPR Therapeutics
CRSP
$4.71B
| $30.3M | 46.45% | 498,558 | – | – |
|
2
Passage Bio
PASG
$22.7M
| $11.7M | 17.94% | 4,959,769 | – | – |
|
|
GRTS
3
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $8.62M | 13.21% | 3,561,150 | – | – |
|
4
Adverum Biotechnologies
ADVM
$64.6M
| $6.08M | 9.32% | 5,068,233 | – | – |
|
|
UTRS
5
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
| $3.93M | 6.03% | 1,673,700 | – | – |
|
6
Aligos Therapeutics
ALGS
$73.3M
| $2.81M | 4.3% | 2,320,381 | – | – |
|
|
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
| $1.6M | 2.46% | 543,753 | – | – |
|
|
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
| $183K | 0.28% | 101,855 | – | – |
|
|
9
Akero Therapeutics
AKRO
$3.74B
| – | – | -617,727 | Closed | -$8.77M |
|
|
10
Crinetics Pharmaceuticals
CRNX
$2.92B
| – | – | -410,360 | Closed | -$9.01M |
|